Praxiszentrum St. Bonifatius München, Munich, Germany.
Charité-University Medicine Berlin, Berlin, Germany.
Curr Med Res Opin. 2020 Sep;36(9):1559-1567. doi: 10.1080/03007995.2020.1790347. Epub 2020 Jul 22.
Golimumab (GLM) has shown its efficacy and safety in various clinical trials. We aimed to assess the effect of GLM on socio economic and health economic parameters in daily clinical practice.
Rheumatology offices in Germany.
Analysis of socio economic and health economic parameters of the non-interventional, multicentre, prospective study GO-NICE. Analyses were performed in an exploratory manner using descriptive statistical methods. Further, values on socio economic variables were calculated based on one-sample t-test on the differences between baseline and follow-up visits.
A total of 1458 patients were evaluable, of whom a total of 664 patients completed the 24-month observation period. The proportions of hospitalizations decreased statistically significantly ( ≤ .05) from 10.4/7.6/14.0% at baseline (BL) to 1.7/2.2/0.8%, and the in-patient rehabilitations decreased from 3.3/3.7/7.5% at BL to 0.6/1.8/2.1% at month 24 in patients with RA, PsA, and AS. When considering a 30-day period, the mean number of sick leave days decreased statistically significantly ( ≤ .005) from 4.0 at BL to 0.9 at month 24 (greatest improvement in RA), and the mean number of days with impaired capability decreased statistically significantly ( ≤ .001) from 14.9 at BL to 4.5 at month 24 (greatest improvement in patients with AS). There was also a reduction in the number of consultations and remedies.
This evaluation shows improvements in socio economic and health economic parameters on GLM treatment.
戈利木单抗（GLM）在各种临床试验中已显示出其疗效和安全性。我们旨在评估 GLM 在日常临床实践中对社会经济和健康经济参数的影响。
德国风湿病科。
对非干预性、多中心、前瞻性研究 GO-NICE 的社会经济和健康经济参数进行分析。使用描述性统计方法进行探索性分析。此外，基于基线和随访访问之间差异的单样本 t 检验，计算社会经济变量的值。
共 1458 例患者可评估，其中 664 例患者完成了 24 个月的观察期。住院比例从基线时的 10.4%/7.6%/14.0%显著下降（≤.05），至 24 个月时的 1.7%/2.2%/0.8%，住院康复从基线时的 3.3%/3.7%/7.5%降至 24 个月时的 0.6%/1.8%/2.1%，RA、PsA 和 AS 患者。考虑到 30 天周期，病假天数从基线时的 4.0 天显著减少（≤.005）至 24 个月时的 0.9 天（RA 患者改善最大），能力受损天数从基线时的 14.9 天显著减少（≤.001）至 24 个月时的 4.5 天（AS 患者改善最大）。就诊次数和药物使用也有所减少。
这项评估显示，GLM 治疗可改善社会经济和健康经济参数。
